Table II.
Meta-analysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of lung cancer.
| Genetic models | OR (95% CI) | I2 (%) | P-value |
|---|---|---|---|
| C677T | |||
| TT vs. CC/CT | |||
| All | 1.24 (1.01–1.52) | 71 | 0.0001 |
| Hospital-based | 1.39 (0.85–2.27) | 85 | 0.0002 |
| Population-based | 1.20 (0.90–1.51) | 63 | 0.005 |
| TT vs. CC | |||
| All | 1.44 (0.86–2.39) | 94 | 0.00001 |
| Hospital-based | 3.01 (1.07–8.46) | 94 | 0.00001 |
| Population-based | 1.02 (0.55–1.89) | 94 | 0.00001 |
| TT/CT vs. CC | |||
| All | 1.15 (0.84–1.56) | 92 | 0.00001 |
| Hospital-based | 1.26 (0.90–1.74) | 77 | 0.004 |
| Population-based | 1.08 (0.71–1.63) | 93 | 0.00001 |
| A1298C | |||
| CC vs. AA/AC | |||
| All | 1.18 (0.88–1.59) | 0 | 0.48 |
| Hospital-based | 1.24 (0.88–1.76) | 0 | 0.44 |
| Population-based | 1.02 (0.57–1.82) | 25 | 0.26 |
| CC vs. AA | |||
| All | 1.18 (0.88–1.59) | 0 | 0.45 |
| Hospital-based | 1.24 (0.87–1.75) | 4 | 0.35 |
| Population-based | 1.04 (0.58–1.86) | 20 | 0.29 |
| CC/AC vs. AA | |||
| All | 1.02 (0.90–1.15) | 0 | 0.76 |
| Hospital-based | 1.01 (0.87–1.17) | 22 | 0.28 |
| Population-based | 1.04 (0.90–1.15) | 0 | 0.76 |
OR, odds ratio; CI, confidence interval.